New Lattice CrossLink-NX FPGAs Bring Power and Performance Leadership to Embedded Vision and Edge AI Applications
11.12.2019 00:00:00 EET | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today announced the first FPGA developed on its new Lattice Nexus™ FPGA platform, CrossLink-NX™. This new FPGA provides the low power, small form factor, reliability, and performance that developers need to create innovative embedded vision and AI solutions for communications, compute, industrial, automotive, and consumer systems.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191210005349/en/
The new CrossLink-NX FPGA from Lattice Semiconductor (Graphic: Business Wire)
According to Patrick Moorhead, President and Founder of Moor Insights & Strategy, “Technology trends like 5G connectivity, cloud-based analytics, factory automation and the smart home are driving demand for embedded vision solutions that support machine learning. However, the data latency, cost and privacy issues associated with cloud-based ML analytics have sparked interest among developers in moving more data processing from the cloud to the Edge. But doing so requires OEMs have access to Edge AI/ML inferencing solutions that offer high performance data processing, low power operation, and a small form factor.”
FPGAs are a compelling hardware platform for embedded vision and AI applications, as they perform functions in parallel. This parallel architecture significantly accelerates certain processing workloads, including data inferencing.
“Embedded vision systems are growing in complexity; many systems today use multiple image sensors, displays and cameras. Implementing such systems at the Edge, where device size and power consumption are critical, adds even more design complexity,” said Bill Pu, Co-Founder and President, Leopard Imaging. “With their very low power consumption, small size, high-performance interfaces, and robust software and IP library, Lattice CrossLink-NX FPGAs let us quickly and easily develop different video signal bridging, aggregation and splitting applications for our industrial and automotive customers using just one device, saving us significant development time and resources.”
The CrossLink-NX family was designed using the new Lattice Nexus platform, which combines a 28 nm FD-SOI manufacturing process with a new, Lattice-designed, FPGA fabric architecture optimized for low power operation in a small form factor.
“Not only does CrossLink-NX lead in power consumption, form factor, reliability and performance in comparison to similar competing FPGAs, it is also supported by a robust library of design software, IP blocks and application reference designs,” said Gordon Hands, Director of Product Marketing, Lattice Semiconductor. “These make it quick and easy for developers to integrate CrossLink-NX FPGAs into new or existing Edge designs.”
Key features of the CrossLink-NX include:
- Low power – built on the Lattice Nexus FPGA platform, CrossLink-NX provides up to a 75 percent reduction in power consumption compared to competing FPGAs of a similar class.
- High reliability – CrossLink-NX has a Soft Error Rate (SER) up to 100 times lower than similar FPGAs in its class, making it a compelling solution for mission critical applications that must operate safely and reliably. The initial CrossLink-NX device is designed to support ruggedized environments found in outdoor, industrial, and automotive applications.
-
Performance – CrossLink-NX delivers enhanced performance enabled by three key elements:
- Fast I/O support – CrossLink-NX FPGAs are well-suited for embedded vision applications thanks to support for multiple fast I/Os, including MIPI, PCIe and DDR3 memory.
- Instant on performance – to better support applications where a long system boot time is unacceptable, such as industrial motor control, CrossLink-NX enables ultra-fast I/O configuration in 3 ms and total device configuration in less than 15 ms.
- High memory to logic ratio – to efficiently power AI inferencing in Edge devices, CrossLink-NX features 170 bits of memory for every logic cell, the highest memory to logic ratio in its class, providing 2x the performance compared to prior generations.
- Small form factor – to support customer system miniaturization, the first CrossLink-NX device is available in a 6 x 6 mm form factor which is up to ten times smaller than similar competing FPGAs in its class.
- Software tools and IP – in addition to its new Lattice Radiant 2.0 design software, Lattice offers a robust library of popular IP cores including interfaces like MIPI D-PHY, PCIe, SGMII and OpenLDI, and demos for common embedded vision applications such as 4:1 image sensor aggregation.
Originally scheduled for availability in 2020, Lattice is releasing CrossLink-NX ahead of schedule and is already sampling devices with select customers. For more information, please visit www.latticesemi.com/CrossLink-NX.
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing communications, computing, industrial, automotive and consumer markets. Our technology, long-standing relationships, and commitment to world-class support lets our customers quickly and easily unleash their innovation to create a smart, secure and connected world.
For more information about Lattice, please visit www.latticesemi.com. You can also follow us via LinkedIn, Twitter, Facebook, YouTube, WeChat, Weibo or Youku.
Lattice Semiconductor Corporation, Lattice Semiconductor (& design) and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005349/en/
Contact information
MEDIA CONTACTS:
Bob Nelson
Lattice Semiconductor
408-826-6339
Bob.Nelson@latticesemi.com
INVESTOR CONTACT:
Rick Muscha
Lattice Semiconductor
408-826-6000
Rick.Muscha@latticesemi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
